STRO vs. ESPR, ANNX, PROK, CRVS, TKNO, MBX, CADL, AQST, SEPN, and ITOS
Should you be buying Sutro Biopharma stock or one of its competitors? The main competitors of Sutro Biopharma include Esperion Therapeutics (ESPR), Annexon (ANNX), ProKidney (PROK), Corvus Pharmaceuticals (CRVS), Alpha Teknova (TKNO), MBX Biosciences (MBX), Candel Therapeutics (CADL), Aquestive Therapeutics (AQST), Septerna (SEPN), and iTeos Therapeutics (ITOS). These companies are all part of the "pharmaceutical products" industry.
Sutro Biopharma vs.
Sutro Biopharma (NASDAQ:STRO) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, community ranking, analyst recommendations, risk and institutional ownership.
Esperion Therapeutics received 495 more outperform votes than Sutro Biopharma when rated by MarketBeat users. Likewise, 70.21% of users gave Esperion Therapeutics an outperform vote while only 64.08% of users gave Sutro Biopharma an outperform vote.
Esperion Therapeutics has a net margin of -29.37% compared to Sutro Biopharma's net margin of -77.01%. Esperion Therapeutics' return on equity of 0.00% beat Sutro Biopharma's return on equity.
Sutro Biopharma currently has a consensus target price of $6.63, indicating a potential upside of 766.01%. Esperion Therapeutics has a consensus target price of $6.75, indicating a potential upside of 307.85%. Given Sutro Biopharma's higher probable upside, equities research analysts clearly believe Sutro Biopharma is more favorable than Esperion Therapeutics.
In the previous week, Esperion Therapeutics had 3 more articles in the media than Sutro Biopharma. MarketBeat recorded 9 mentions for Esperion Therapeutics and 6 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 0.59 beat Esperion Therapeutics' score of 0.49 indicating that Sutro Biopharma is being referred to more favorably in the media.
97.0% of Sutro Biopharma shares are held by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are held by institutional investors. 5.9% of Sutro Biopharma shares are held by company insiders. Comparatively, 1.0% of Esperion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Sutro Biopharma has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.
Sutro Biopharma has higher earnings, but lower revenue than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.
Summary
Esperion Therapeutics beats Sutro Biopharma on 10 of the 18 factors compared between the two stocks.
Get Sutro Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sutro Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:STRO) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy STRO Stock Free STRO Stock Alerts